Browse the evidence

Obesity (BMI ≥30 kg/m²) is a major risk factor for the development, recurrence, and mortality of several solid-organ and hematological malignancies, including post-menopausal breast, colorectal, endometrial, kidney, esophageal, pancreatic, liver, and gallbladder cancers.

Maintaining a healthy body weight (BMI <25) is a critical strategy for reducing the risk of developing several common cancers, particularly post-menopausal breast, colorectal, and endometrial cancers. For cancer survivors, weight management is essential to reduce the risk of recurrence and improve survival outcomes.

GLP-1 receptor agonists (specifically liraglutide, subcutaneous semaglutide, and dulaglutide) significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes, independent of glucose-lowering effects.

If you have Type 2 Diabetes and established heart disease or high risk, ask your doctor about GLP-1 receptor agonists like liraglutide, semaglutide, or dulaglutide. These drugs are proven to significantly lower your risk of heart attack, stroke, and cardiovascular death, regardless of how well they control your blood sugar. They are now a standard recommendation in guidelines for high-risk patients.

For South and Southeast Asian populations, obesity diagnostic thresholds should be lowered (BMI ≥23 kg/m² for overweight, ≥25 kg/m² for obesity) because Asians exhibit higher visceral adiposity and cardiometabolic risk at lower BMIs compared to Caucasian populations.

If you are of South or Southeast Asian descent, do not rely solely on the standard BMI cutoff of 30 to define obesity. Your health risks for diabetes and heart disease increase at lower weights. Use the lower thresholds (Overweight ≥23, Obese ≥25) or waist circumference measurements to assess your risk, and consult a clinician for a full metabolic workup even if your BMI appears 'normal' by international standards.

Discontinuation of second-generation anti-obesity medications (semaglutide and tirzepatide) leads to rapid and substantial weight regain, often returning to baseline cardiometabolic status, demonstrating the chronic nature of obesity and the need for indefinite treatment.

If you stop taking semaglutide or tirzepatide, you will likely regain most of the weight you lost within a year. This demonstrates that obesity is a chronic condition requiring long-term treatment, similar to high blood pressure. To maintain weight loss, you likely need to continue the medication indefinitely.

SGLT2 inhibitors reduce the risk of heart failure, cardiovascular events, and renal progression in patients with type 2 diabetes, independent of glycemic control.

If you have type 2 diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors. They protect your heart and kidneys, not just your blood sugar.

Semaglutide reduces cardiovascular risk (MACE) and non-ASCVD deaths (including from infections) in overweight/obese patients with established cardiovascular disease, independent of diabetes status.

If you are overweight or obese and have heart disease, semaglutide 2.4mg weekly can reduce your risk of heart attack, stroke, and death by 20%, even if you don't have diabetes. It may also reduce death from infections.

GLP-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk, primarily by reducing non-fatal myocardial infarction and stroke.

If you have Type 2 Diabetes and are at high risk for heart disease, GLP-1 receptor agonists (like semaglutide or liraglutide) are a primary treatment option that not only lowers blood sugar but significantly reduces the risk of heart attack and stroke. These medications are taken via injection (daily or weekly) and have been shown in large clinical trials to improve cardiovascular outcomes compared to placebo.

Obesity, particularly visceral adipose tissue (VAT) accumulation, promotes cardiovascular disease through mechanisms including chronic inflammation, insulin resistance, and endothelial dysfunction, leading to conditions like hypertension, atherosclerosis, and heart failure.

Obesity is not just about weight; it causes real physical changes in your body, especially around your belly (visceral fat), that increase your risk of heart disease, high blood pressure, and diabetes. These changes involve inflammation and hormonal imbalances that damage your blood vessels and heart. Understanding this helps explain why treating obesity is crucial for long-term heart health, not just appearance.

Total daily energy expenditure (TDEE) in healthy, free-living, non-athlete individuals is primarily composed of resting energy expenditure (approx. 60%), physical activity energy expenditure (approx. 30%), and the thermic effect of food (approx. 10%).

To understand your daily energy needs, recognize that most energy (60%) is used just to keep your body running at rest, about 30% goes to movement, and 10% is used to digest food. This breakdown helps in estimating caloric requirements for health maintenance.

Physical activity energy expenditure (PAEE) is highly variable among individuals and can range from almost none in bedridden individuals to approximately 50% of TDEE in highly active individuals.

Your physical activity level is the most variable component of your daily energy expenditure. Increasing your movement can significantly increase your total energy needs.

SGLT2 inhibitors and GLP-1 agonists provide significant cardiovascular and renal protection in Type 2 Diabetes, independent of their glucose-lowering effects.

If you have Type 2 Diabetes and are at risk for heart or kidney problems, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These medications have been shown to protect your heart and kidneys, offering benefits beyond just lowering blood sugar.

Females achieve similar relative increases in muscle mass and strength compared to males following resistance exercise training, despite having significantly lower systemic testosterone concentrations.

Women should not fear that resistance training will make them 'too bulky' compared to men. Your body responds to resistance training with similar relative gains in muscle size and strength as men, despite having lower testosterone. Focus on progressive overload just as you would for a male partner.

Discontinuation of GLP-1 therapy leads to rapid and substantial weight regain, often returning to near baseline levels within one year, highlighting the chronic nature of obesity treatment.

GLP-1 medications are not a one-time fix for obesity. If you stop taking them, you will likely regain most of the weight you lost. This suggests that obesity management with these drugs is intended to be long-term, similar to managing blood pressure or cholesterol.

Long-acting GLP-1 receptor agonists (e.g., semaglutide 2.4 mg) and multi-agonists (e.g., tirzepatide) produce significant, dose-dependent weight loss (10-21%) in adults with obesity, but discontinuation leads to substantial weight regain, indicating these are chronic management tools rather than cures.

GLP-1 and multi-agonist medications are highly effective for significant weight loss (10-20%+), but they are not cures. You must take them long-term to maintain results. If you stop, your body will likely fight to regain the weight. Expect some stomach issues initially, but these often fade. Work with your doctor to find the right dose.

GLP-1 receptor agonists (specifically liraglutide, semaglutide, and dulaglutide) significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk, independent of baseline BMI.

If you have Type 2 Diabetes and high heart risk, GLP-1 medications like liraglutide, semaglutide, or dulaglutide are proven to significantly lower your risk of heart attack, stroke, and heart-related death. These benefits exist even if your weight loss isn't massive. Discuss these options with your doctor, especially if you have existing heart disease.

SGLT2 inhibitors (specifically empagliflozin and canagliflozin) reduce major adverse cardiovascular events (MACE) in patients with Type 2 Diabetes, with empagliflozin also reducing heart failure hospitalizations.

If you have Type 2 Diabetes and heart risk, SGLT2 inhibitors like empagliflozin or canagliflozin can significantly lower your risk of heart attack, stroke, and heart failure hospitalization. These drugs work by removing excess sugar through urine. Discuss these with your doctor, especially if you have heart failure.

GLP-1 RAs reduce Major Adverse Cardiovascular Events (MACE) by 14-20% in patients with Type 2 Diabetes and Obesity, independent of glycemic control.

GLP-1 medications significantly reduce the risk of heart attacks, strokes, and cardiovascular death in people with diabetes or obesity. This benefit exists even if blood sugar control is not the primary goal. Discuss cardiovascular risk with your doctor to see if a GLP-1 RA is appropriate.

Current pharmacological treatments for obesity, including incretin-based therapies (semaglutide, tirzepatide), result in significant skeletal muscle loss (approx. 7-10% of lean mass) alongside fat loss.

If you are using GLP-1 medications, expect to lose some muscle. You must actively combat this by eating enough protein and doing resistance training to preserve your metabolic engine.

GLP-1 agonists reduce cardiovascular risk and all-cause mortality in diabetic populations, offering a secondary benefit for OSA patients who have high cardiometabolic risk.

For OSA patients with diabetes or high heart disease risk, GLP-1 agonists provide dual benefits: improving sleep apnea and reducing long-term cardiovascular mortality.

Resmetirom (Rezdiffra), a thyroid hormone receptor-beta (THR-β) agonist, is the first FDA-approved pharmacotherapy for non-cirrhotic MASH in adults with moderate to advanced liver fibrosis (F2-F3), demonstrating significant resolution of MASH and improvement in liver fibrosis compared to placebo.

If you have non-cirrhotic MASH with moderate to advanced fibrosis, ask your doctor about Resmetirom (Rezdiffra). It is the first FDA-approved drug for this condition, taken orally alongside diet and exercise, and has been shown to significantly improve liver health compared to placebo.

Subcutaneous semaglutide (0.5-1.0 mg) and oral semaglutide (7-14 mg) significantly improve glycemic control (HbA1c reduction) in patients with type 2 diabetes compared to placebo and various active control drugs.

For individuals with type 2 diabetes, semaglutide (available as a once-weekly injection or daily oral tablet) is highly effective at lowering blood sugar levels (HbA1c) compared to many other treatments, including insulin and other common diabetes medications. It offers a significant advantage in achieving target HbA1c levels (<7%) for a large proportion of patients. The risk of hypoglycemia is relatively low, and the once-weekly dosing can help improve compliance.

Individuals with Type 2 Diabetes (T2D) exhibit significantly reduced cardiorespiratory fitness (CRF), measured as peak oxygen uptake (VO2peak), compared to healthy controls, with reductions averaging 13.9% for absolute VO2peak and 17.4% for relative VO2peak.

If you have Type 2 Diabetes, expect your maximum oxygen uptake to be lower than a healthy peer's, even if you feel fine. This is a physiological marker of the disease, not a lack of effort. Start exercise interventions at a lower intensity to manage early fatigue, and focus on consistency rather than high intensity initially, as improving this baseline fitness is critical for long-term health outcomes.

Among patients with type 2 diabetes in placebo-controlled trials, baseline BMI has significantly increased over time (rising by ~0.70 kg/m² per decade), indicating a growing prevalence of obesity and inadequate management of weight despite improved glycemic control.

If you have Type 2 Diabetes, your weight is likely increasing even if your blood sugar is controlled. This meta-analysis of over 260,000 patients shows that baseline BMI has risen by 0.7 kg/m² every decade. You cannot ignore weight management; it is becoming harder, not easier, to maintain a healthy weight with current standard care. Focus on energy balance (diet and activity) as rigorously as you focus on glucose numbers.

Baseline HbA1c levels in Type 2 Diabetes patients have significantly declined over time (from ~10.6% to ~7.9%), reflecting improved glycemic control in clinical trial populations.

Blood sugar control in Type 2 Diabetes has improved significantly over the last 35 years, with average baseline HbA1c dropping from 10.6% to 7.9%. This suggests that modern detection and management strategies are more effective. However, this improvement in glucose control has not prevented the rise in obesity, meaning you must address both metrics.